VC-backed Inhibrx debuts IPO
La Jolla, California-based Inhibrx Inc, a clinical-stage biotech company, has raised $119 million for its IPO after pricing its 7 million shares at $17 per share.
La Jolla, California-based Inhibrx Inc, a clinical-stage biotech company, has raised $119 million for its IPO after pricing its 7 million shares at $17 per share.
Copyright PEI Media
Not for publication, email or dissemination